Advanced search
Publication Cover
Journal of Medical Economics Volume 18, 2015 - Issue 10
Submit an article Journal homepage
1,250
Views
11
CrossRef citations to date
0
Altmetric
Original article

Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China

Shuyan GuCenter for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, PR China
,
Jing DengDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
,
Lizheng ShiDepartment of Global Health Systems and Development, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA
,
Yiming MuDepartment of Endocrinology and Metabolism, Chinese PLA General Hospital, Chinese PLA Medical College, Beijing, PR China
&
Hengjin DongCenter for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, PR ChinaCorrespondence[email protected]
Pages 808-820 | Accepted 06 May 2015, Published online: 01 Jul 2015

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi & Hao Hu. (2022) Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 555-574.
Read now
Ching-Lun Chien, Yen-Chou Chen, Daniel C. Malone, Yueh-Lung Peng & Yu Ko. (2020) Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Current Medical Research and Opinion 36:10, pages 1619-1626.
Read now

Articles from other publishers (9)

Lona Mhlaba, Dineo Mpanya & Nqoba Tsabedze. (2023) HbA1c control in type 2 diabetes mellitus patients with coronary artery disease: a retrospective study in a tertiary hospital in South Africa. Frontiers in Clinical Diabetes and Healthcare 4.
Crossref
Jiejin Zhu, Ying Zhou, Qingyu Li & Gang Wang. (2023) Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review. Advances in Therapy.
Crossref
Kah Yee Lum, Raymond Oppong & Jesse Kigozi. (2022) Economic Evaluation of Type 2 Diabetes Mellitus Interventions in Low- and Middle-Income Countries: A Systematic Review of the Literature. Asia Pacific Journal of Public Health 34:8, pages 752-760.
Crossref
Mengistu Bekele, Ole Frithjof Norheim & Alemayehu Hailu. (2021) Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia. MDM Policy & Practice 6:1, pages 238146832110057.
Crossref
Shanshan Hu, Xun Deng, Yanjiao Ma, Zhilei Li, Yuhang Wang & Yong Wang. (2020) Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus. Applied Health Economics and Health Policy 19:1, pages 69-79.
Crossref
Shuyan Gu, Lizheng Shi, Hui Shao, Xiaoyong Wang, Xiaoqian Hu, Yuxuan Gu & Hengjin Dong. (2020) Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. BMC Medicine 18:1.
Crossref
Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria-Inti Metzendorf, Bernd Richter & Bianca Hemmingsen. (2019) Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Corrina Moucheraud, Cosima Lenz, Michaella Latkovic & Veronika J Wirtz. (2019) The costs of diabetes treatment in low- and middle-income countries: a systematic review. BMJ Global Health 4:1, pages e001258.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.